Asset Details
Do you wish to reserve the book?
Genetic Variation in IL-1β, IL-2, IL-6, TSPO and BDNF and Response to Duloxetine or Placebo Treatment in Major Depressive Disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Genetic Variation in IL-1β, IL-2, IL-6, TSPO and BDNF and Response to Duloxetine or Placebo Treatment in Major Depressive Disorder
Do you wish to request the book?
Genetic Variation in IL-1β, IL-2, IL-6, TSPO and BDNF and Response to Duloxetine or Placebo Treatment in Major Depressive Disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Genetic Variation in IL-1β, IL-2, IL-6, TSPO and BDNF and Response to Duloxetine or Placebo Treatment in Major Depressive Disorder
2015
Overview
This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression.
Twenty SNPs in IL-1β, IL-2, IL-6, TSPO and BDNF were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale.
IL-6 variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing.
Our findings tentatively suggest that IL-6 variants play a role in duloxetine and placebo response, which warrants further investigation.
Publisher
Future Medicine Ltd
Subject
/ Antidepressive Agents - therapeutic use
/ Brain-derived neurotrophic factor
/ Brain-Derived Neurotrophic Factor - genetics
/ Depressive Disorder, Major - diagnosis
/ Depressive Disorder, Major - drug therapy
/ Depressive Disorder, Major - genetics
/ Dose-Response Relationship, Drug
/ Duloxetine Hydrochloride - therapeutic use
/ Female
/ Genetic Variation - genetics
/ Humans
/ IL-1β
/ Interleukin-1beta - genetics
/ Male
/ Single-nucleotide polymorphism
/ Studies
